VIP-1: extended-release verapamil in Stage 1 preclinical T1D
What this study tests
A randomized, double-blind, placebo-controlled phase 2/3 trial in France testing whether 48 weeks of extended-release oral verapamil preserves beta-cell function in children and adults with Stage 1 (normoglycemic, multiple-autoantibody-positive) T1D.
Editorial review: .
Registry checked: 2026-10-19. Registry’s own update: 2026-10-19.
Most recent recorded citation date: 2026-10-19. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Children and adults aged 7–45 years with Stage 1 T1D (presence of at least two islet autoantibodies without dysglycemia) and body weight at least 30 kg. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. Registry checked 19 October 2026 (ClinicalTrials.gov first posted 19 October 2026; EU CTIS 2025-524318-27-00 authorised 5 August 2026): not yet recruiting; estimated n=50; estimated primary completion March 2031.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Beta-cell function index (OGTT/MMTT C-peptide model) at 48 weeks
The full picture
What the study asks
VIP-1 is a randomized, double-blind, placebo-controlled phase 2/3 trial sponsored by Assistance Publique – Hôpitaux de Paris evaluating whether 48 weeks of once-daily extended-release oral verapamil preserves beta-cell function in individuals with Stage 1 (preclinical, normoglycemic) type 1 diabetes.12
Who it involves
Children and adults aged 7–45 years with Stage 1 type 1 diabetes (at least two positive islet autoantibodies and normal glucose tolerance) weighing at least 30 kg. Cardiac conduction, hypotension, and other standard verapamil exclusions apply.1
Design and timing
The registry lists an estimated enrollment of 50 participants in France, with an estimated start date of January 2027 and estimated primary and study completion in March 2031. The primary endpoint evaluates a modeled beta-cell function index derived from oral glucose tolerance test (OGTT) / mixed-meal tolerance test (MMTT) C-peptide measurements at 48 weeks.12
Evidence and limits
No results are posted, and the trial is not yet recruiting. Earlier verapamil trials (such as CLVer and Ver-A-T1D) studied newly diagnosed Stage 3 type 1 diabetes; whether verapamil alters progression in Stage 1 normoglycemic autoimmunity remains untested.1
Sources
- [1]Verapamil in Preclinical Type 1 Diabetes (VIP-1, NCT07880769) · Trial registry · 2026-10-19 — Protocol and current registry status checked 19 October 2026: NOT_YET_RECRUITING; estimated n=50; first posted 19 October 2026; no results posted.
ClinicalTrials.gov. NCT07880769 (secondary ID 2025-524318-27-00). Record checked 19 October 2026; first posted 2026-10-19.
- [2]VIP-1 EU Clinical Trials Information System Record (2025-524318-27-00) · Trial registry · 2026-08-05 — Authorised in France on 5 August 2026 under EU CTIS number 2025-524318-27-00; checked 19 October 2026.
EU Clinical Trials Information System (CTIS). EUCT 2025-524318-27-00 (VIP-1). Authorised 5 August 2026; checked 19 October 2026.